Physician profile
Ryan Harris
NPI 1114338993
$2,970.67
in general payments reported to CMS, 2019-2025
19 companies · $387 in 2025
The $387 reported for 2025 was more than what 87% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $265 · 2021: $701 · 2022: $237 · 2023: $389 · 2024: $653 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $445.31 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $436.66 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $396.95 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $394.89 | 2021-2025 | |
| Abbvie INC. | $251.20 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $183.86 | 2020-2025 | Zerbaxa, Dificid, Recarbrio |
| Astrazeneca Pharmaceuticals LP | $175.67 | 2020-2023 | Andexxa |
| Gilead Sciences, INC. | $129.56 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $113.06 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.76 | 2022-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $76.16 | 2021-2024 | Ultomiris |
| Boston Scientific Corporation | $76.12 | 2021-2024 | Watchman Flx |
| Sk Life Science, INC. | $70.86 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.58 | 2019 | |
| Ucb, INC. | $21.70 | 2024 | Briviact |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $21.01 | 2023 | |
| Novo Nordisk INC | $19.76 | 2024 | Rybelsus |
| Paratek Pharmaceuticals, INC. | $15.09 | 2022 | |
| Allergan, INC. | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.